BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
After market 07:59:42 pm | |||
| 40.49 USD | -1.82% |
|
40.52 | +0.07% |
| May. 28 | Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License | MT |
| May. 27 | Bristol Myers: will present data on schizophrenia | CF |
Financials (USD)
| Sales 2024 * | 46.09B | Sales 2025 * | 46.06B | Capitalization | 82.08B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.41B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.63 x |
| Net Debt 2024 * | 39.03B | Net Debt 2025 * | 31.68B | EV / Sales 2025 * | 2.47 x |
| P/E ratio 2024 * |
-15.4
x | P/E ratio 2025 * |
7.66
x | Employees | 34,100 |
| Yield 2024 * |
5.94% | Yield 2025 * |
6.24% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | +0.07% | ||
| 1 week | -4.21% | ||
| Current month | -7.85% | ||
| 1 month | -9.72% | ||
| 3 months | -20.48% | ||
| 6 months | -17.23% | ||
| Current year | -21.09% |
1 week
40.38
42.27
1 month
40.3845.72
Current year
40.3855.04
1 year
40.3866.46
3 years
40.3881.44
5 years
40.3881.44
10 years
40.3881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +12.51% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 40.49 | -1.82% | 14,674,452 |
| 24-05-24 | 41.24 | -0.72% | 17,425,597 |
| 24-05-23 | 41.54 | -1.89% | 12,437,959 |
| 24-05-22 | 42.34 | +0.17% | 16,786,014 |
| 24-05-21 | 42.27 | -2.51% | 17,576,788 |
Delayed Quote Nyse, May 28, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.49
USD
Average target price
53.19
USD
Spread / Average Target
+31.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.09% | 82.08B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- BMY Stock
